EyePoint制药公司(EYPT)股价在10月29日盘前大跌7.34%,引发了市场的广泛关注。
导致该公司股价下跌的主要原因是,公司宣布公开发行价值1亿美元的新股。这一举措将增加公司股票供应量,导致现有股东的权益遭到进一步稀释,因此引发了投资者的担忧情绪。
根据公告,此次发行由摩根大通、花旗集团和古根海姆证券三家公司联合担任簿记管理人。股价在盘后一度进一步下跌8.5%至11.09美元。不过,EyePoint表示将利用此次发行所得资金继续推进其糖尿病黄斑水肿药物Duravyu的开发工作,并支持其他早期管线产品的研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.